Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Teva swoops on Auspex with $3.2bn acquisition

This article was originally published in Scrip

Executive Summary

Teva Pharmaceutical Industries has agreed to acquire Auspex Pharmaceuticals in an all cash deal valuing the CNS-focused firm at $3.2bn. Teva executives underlined that the deal did not preclude other, bigger, deals that it is still hoping to make.

You may also be interested in...



Teva Set For Immediate US Launch Of Austedo In Tardive Dyskinesia

FDA-approved labeling includes boxed warning for depression and suicidality, though this is specific for Huntington's disease patients, who are prone to these conditions.

Scrip Asks…What Does 2023 Hold For Biopharma? Part 5: Technological Advances

The confluence of data science and molecular biology fuels expectations among biopharma industry leaders for another year of breakthrough innovation in human therapeutics. More than 70 executives and experts reveal what they are most excited about on the technology front.

Scrip Asks… What Does 2023 Hold For Biopharma? Part 4: Pricing And Reimbursement

Biopharma executives see value-based pricing as an increasingly important topic for the sector in 2023, while the US Inflation Reduction Act will have a major impact on portfolio strategies.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC028271

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel